The Influence of Immunoglobulin Dosage and Administration on Development of Hemolytic Anemia and Variation on Muscle Strength in Patients With CIDP and MMN

Trial Profile

The Influence of Immunoglobulin Dosage and Administration on Development of Hemolytic Anemia and Variation on Muscle Strength in Patients With CIDP and MMN

Completed
Phase of Trial: Phase IV

Latest Information Update: 31 May 2016

At a glance

  • Drugs Immune globulin (Primary) ; Immune globulin (Primary)
  • Indications Chronic inflammatory demyelinating polyradiculoneuropathy; Multifocal motor neuropathy
  • Focus Adverse reactions
  • Most Recent Events

    • 21 Sep 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 04 May 2015 Planned End Date changed from 1 Mar 2015 to 1 Dec 2015 as per ClinicalTrials.gov record.
    • 04 May 2015 Planned primary completion date changed from 1 Mar 2015 to 1 Aug 2015 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top